Regenxbio presents long-term data for surabgene lomparvovec

Regenxbio (RGNX) announced positive data from long-term follow-up studies of investigational surabgene lomparvovec in wet AMD using subretinal delivery and diabetic retinopathy, DR, using suprachoroidal delivery. These new data were presented at the American Society of Retina Specialists, ASRS, 44th Annual Meeting in Montreal, Canada. One-time gene therapy treatment with sura-vec demonstrated long-term efficacy at similar doses to those being evaluated in ongoing late-stage studies: Stable to improved vision through 5 years in wet AMD patients who required frequent anti-VEGF injections prior to one-time sura-vec; no drug-related IOI observed in a setting of no prophylactic steroids; Prevention of vision-threatening events without any additional treatment and greater than2-step DRSS improvement in majority of NPDR participants at 2.5 years; no IOI observed with short-course prophylactic topical steroids. Topline data from wet AMD pivotal studies, Atmosphere and Ascent, expected in Q4 2026

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on RGNX:

Disclaimer & DisclosureReport an Issue